Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of KYMR is 69 and suggests 18% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell